Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DAO | P14920 | 14/20 | 0.61 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.43 |
| ▸ | GLA | P06280 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | PKM | P14618 | 1/20 | 0.38 |
| ▸ | COMT | P21964 | 1/20 | 0.37 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19049572 | 0.85 | DAO (0.56) | DAOCOMT | |
| SCHEMBL5796354 | 0.78 | KDM4C (0.43) | DAOKDM4CGLA | |
| SCHEMBL18997760 | 0.76 | DAO (0.51) | DAOCOMT | |
| SCHEMBL19002599 | 0.75 | KDM4E (0.49) | DAOKDM4CGLAKDM4E | |
| SCHEMBL28286935 | 0.71 | MPO (0.44) | KDM4CGLA | |
| SCHEMBL9425091 | 0.71 | BRS3 (0.38) | GLAKDM4EPKM | |
| SCHEMBL7424613 | 0.70 | MMP2 (0.48) | GLAKDM4EPKM | |
| SCHEMBL24445917 | 0.70 | — | — | |
| SCHEMBL7484552 | 0.70 | GLA (0.39) | KDM4CGLA | |
| SCHEMBL3176990 | 0.70 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170174699-A1 | COMPOUNDS FOR THE TREATMENT OF CANCER AND INFLAMMATORY DISEASE | SHY Therapeutics LLC | 2017-06-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170174699-A1 | COMPOUNDS FOR THE TREATMENT OF CANCER AND INFLAMMATORY DISEASE | MAPK6, MAP3K6, MAPK4 | DAO 3864/4885KDM4C 3881/4885GLA 1765/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.